- Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed “encouraging” results.
- Moderna announced Monday that all 45 volunteers in the trial produced antibodies to protect against COVID-19 infection. Shares jumped as much as 39% on the news.
- The new price target implies a 25% leap from Moderna’s price at 12:25 p.m. ET.
- Analyst Salveen Richter raised the vaccine’s probability of success to 75% from 70%, and projected phase-two studies will begin this quarter.
Moderna has a new biggest bull on Wall Street who sees the biotech’s stock surging on its experimental coronavirus vaccine.
Goldman Sachs lifted its 12-month price target for Moderna shares to $105 from $63 on Monday, citing “encouraging” results from the company’s mRNA-1273 treatment. The company announced Monday that all 45 volunteers in a phase-one trial produced antibodies that may protect them from COVID-19.
Goldman analyst Salveen Richter raised the program’s probability of success to 75% from 70% following the positive results. The bank is “optimistic on the forward outlook for the vaccine” and expects phase-two trials to begin in the current quarter. Phase-three studies will start in July, Richter estimated.
Goldman’s new target implies a 25% jump from the stock’s price as of 12:25 p.m. ET. The new target surpasses the previous Wall Street high of $83.
Moderna shares have more than quadrupled in the year-to-date as the firm races to develop the first coronavirus vaccine. The company hopes to have a vaccine ready for use by the fall, fast-tracking the trial process as global COVID-19 cases continue to soar.
Moderna has 11 “buy” ratings and one “hold” rating from analysts, according to Bloomberg data.
By Ben Winck